Paul Dieppe of the University of Bristol attempts to explain aspects of the VIOXX matter using complicity theory. His article is interesting reading and thanks to Pharmagossip for the link.
I think deciphering why things happen is a bit like interpreting poems to discern what did the author really mean. It is an interesting exercise and often we seem to feel better when we "know" why things happen but in the end is it anything more than speculation?
Dieppe says in part:
"Complicity works like that. All those with a vested interest in an enterprise get sucked into the rhetoric associated with it, and they soon ' believe' in everything that is going on within that enterprise. If personal financial gain is involved, corruption may also occur."
How much they believe and how much "they go along to get along" is hard to determine but it is clear that people in groups do things they would never do on their own.
Featured Post
Is the new professionalism and ACP's new ethics really just about following guidelines?
The Charter ( Medical Professionalism in the New Millennium.A Physician's Charter) did not deal with just the important relationship of ...
Thursday, June 29, 2006
Thursday, June 22, 2006
'Unanticipated" effects of the quality movement-JAMA commentary
Dr. Robert M. Wachter, of UCSF, is well known in medical circles for his writing and activities in the hospitalist phenomenon. In the June 21, 2006 issue of JAMA he writes about the quality and IT "revolutions".
His comments about the unforeseen effects of the quality movement resonant with me and likely many real life physicians who may have found the quality activities impeded their work as doctors.I quote:
" More typically, individuals and institutions begin to focus on improving their performance on the variable measure, in doing so turning away from others. This "playing for the test" is not only expected; in some cases it is the point of the whole exercise."
He comments on the most egregious examples of IT gone bad with the Cedars-Sinai debacle and the tragic increase in pediatric deaths occurring after the introduction of a commercial computer system.(Han,YY et al,Pediatrics,2005:116-1506-1512.)
With those facts on the table I find the following puzzling:
"Importantly,until the science of guidelines development and quality measurement improves, the systems must preserve physician's' ability to apply the art of medicine when patients do not fit the templates, such as in those patients with multisystem illness or rapidly changing disease course."
Of course, physicians must have the final say in clinical management,they cannot be replaced with computers and algorithms. The individual physician must be able to deal with the unique particulars of the case at hand. Wachter's use of the word "until" makes me flinch. He seems to believe that someday computers and IT system and EBM and algorithms will get to the point when physicians will not have to apply the art of medicine and will not be allowed to do so. We cannot escape the contingencies of life and medicine by all encompassing algorithms and computer prompts. I don't really think that Dr. Wachter thinks we can escape them but I worry about that "until".
His comments about the unforeseen effects of the quality movement resonant with me and likely many real life physicians who may have found the quality activities impeded their work as doctors.I quote:
" More typically, individuals and institutions begin to focus on improving their performance on the variable measure, in doing so turning away from others. This "playing for the test" is not only expected; in some cases it is the point of the whole exercise."
He comments on the most egregious examples of IT gone bad with the Cedars-Sinai debacle and the tragic increase in pediatric deaths occurring after the introduction of a commercial computer system.(Han,YY et al,Pediatrics,2005:116-1506-1512.)
With those facts on the table I find the following puzzling:
"Importantly,until the science of guidelines development and quality measurement improves, the systems must preserve physician's' ability to apply the art of medicine when patients do not fit the templates, such as in those patients with multisystem illness or rapidly changing disease course."
Of course, physicians must have the final say in clinical management,they cannot be replaced with computers and algorithms. The individual physician must be able to deal with the unique particulars of the case at hand. Wachter's use of the word "until" makes me flinch. He seems to believe that someday computers and IT system and EBM and algorithms will get to the point when physicians will not have to apply the art of medicine and will not be allowed to do so. We cannot escape the contingencies of life and medicine by all encompassing algorithms and computer prompts. I don't really think that Dr. Wachter thinks we can escape them but I worry about that "until".
Wednesday, June 21, 2006
Are Phase IV trials really "seed" trials-another way to manipulate physician behavior?
Dr. Bruce M. Psaty, a prominent clinical epidemiologist from Seattle, plunges into the topic of Phase IV drug trials in the June 21, 2006 issue of JAMA.
Phase IV trials are post marketing trials that,quotes Psaty, were discussed in a 1994 NEJM article by former FDA head David Kessler as a main technique to promote "me too" drugs.
Kessler said:
...because they are, in fact, thinly veiled attempts to entice doctors to prescribe a new drug being marketed by the company,they are often referred to as "seed trials"...[features include]the use of a design that does not support the stated research goals,the recruitment of investigators not because they are experts or leading researchers but because they are frequent prescribers of competing products [and] sponsorship of the studies by the company's sales and marketing division rather than its research department."
Clearly these seed trials are not high quality studies.Psaty talks about what distinguishes high quality studies. Randomization is not enough.
Psaty says that blood pressure drugs are commonly promoted in these trials.
"industry has supported thousands of small short-term randomized trials..."
Most of these seed trials proudly promote themselves as "randomized" and many are but randomization does not equate to a quality trial nor to one that asks a worthwhile scientific question or is otherwise well designed. As Psaty says other features need be present such as blinding,completeness of followup,ascertainment of outcomes to name a few.Randomization is not a sufficient condition for a trial to be worthwhile and/or meaningful and non-trivial.
At times,big pharma and the contract research organizations have taken some of the concepts and rhetoric of EMB and misused them to promote various products by funding and executing these largely bogus seed trials which may have influenced not only the physicians who participate in them but the other physicians who hear from the "thought leaders" how these randomized trials favor one brand over the other. A veneer of evidence based medicine is glued over what is no more than a promotional activity. If big pharma may have corrupted the EBM process, how should the physicians who take part in them be characterized?
Two nouns come to mind; dupes and co-conspirators and I wish I could think of some less pejorative words as alternatives. Some are simply naive and do not understand what is really going on. Some of the academics, however, probably cannot plead ignorance. They either know better or at least in recent years should know better.
Phase IV trials are post marketing trials that,quotes Psaty, were discussed in a 1994 NEJM article by former FDA head David Kessler as a main technique to promote "me too" drugs.
Kessler said:
...because they are, in fact, thinly veiled attempts to entice doctors to prescribe a new drug being marketed by the company,they are often referred to as "seed trials"...[features include]the use of a design that does not support the stated research goals,the recruitment of investigators not because they are experts or leading researchers but because they are frequent prescribers of competing products [and] sponsorship of the studies by the company's sales and marketing division rather than its research department."
Clearly these seed trials are not high quality studies.Psaty talks about what distinguishes high quality studies. Randomization is not enough.
Psaty says that blood pressure drugs are commonly promoted in these trials.
"industry has supported thousands of small short-term randomized trials..."
Most of these seed trials proudly promote themselves as "randomized" and many are but randomization does not equate to a quality trial nor to one that asks a worthwhile scientific question or is otherwise well designed. As Psaty says other features need be present such as blinding,completeness of followup,ascertainment of outcomes to name a few.Randomization is not a sufficient condition for a trial to be worthwhile and/or meaningful and non-trivial.
At times,big pharma and the contract research organizations have taken some of the concepts and rhetoric of EMB and misused them to promote various products by funding and executing these largely bogus seed trials which may have influenced not only the physicians who participate in them but the other physicians who hear from the "thought leaders" how these randomized trials favor one brand over the other. A veneer of evidence based medicine is glued over what is no more than a promotional activity. If big pharma may have corrupted the EBM process, how should the physicians who take part in them be characterized?
Two nouns come to mind; dupes and co-conspirators and I wish I could think of some less pejorative words as alternatives. Some are simply naive and do not understand what is really going on. Some of the academics, however, probably cannot plead ignorance. They either know better or at least in recent years should know better.
Sunday, June 18, 2006
Could the SMART trial have been better designed to bring about the results that GSK did not want?
More than one pulmonary disease specialist has referred to the SMART trial as the [not so] SMART trial. Its design is subject to criticism both in terms of what was offered to the patient volunteers and what was likely to happen in terms of results?
GSK was faced with the task of designing and executing a large clinical trial that had been brought about because of concern that salmeterol might be harmful to some patients with asthma. An earlier trial in Great Britain had shown a numerical increase in salmeterol treated patients that was not statistically significant. One lingering popular explanation for any possible increase in salmeterol treated patient death is that these patients were either under poor control at the beginning of the trial and/or perhaps used the medications improperly or inadequately.
So, what did they do?They recruited patients by advertisements, insuring a high proportion of patients who might not have been receiving good physician care, gave them either salmeterol or placebo and then provided only monthly telephone followup. At this point we have a group of patients, many of whom were not under good control or receiving regular physician hands-on follow up, who were given a medication that was purportedly possibly harmful and not monitored other than by telephone calls. They could not be accused of "cherry-picking" their study subjects in this trial.
This "phase one " recruitment ended when it appeared the trial would need over 60,000 participants (over twice what the original power computation indicated because of the relatively low mortality rate in both the control and treatment arms) and the recruitment process shifted to study investigators who recruited their own patients.This change brought about a situation at least resembling how the drug might be used in clinical practice.
There was a marked difference in the outcomes based on the method of recruitment. 13 of the 16 asthma related deaths occurred in patients recruited in phase one ( figure 2 in the SMART article in CHEST).There were about 15,00 patients in phase one versus about 11,000 in phase
2. The report's table 7 indicates that there were no statistically significant differences between salmeterol and placebo in any of the primary or secondary outcome measures in the phase 2 patients.
If there had been no phase 1 recruitment, there would likely be no black box warning on salmeterol containing products. It should be noted that this trial was terminated early by GSK. Only half of the subjects had been enrolled and the predefined criteria for terminations had not been met.The reasons given were the disproportionate number of events in African Americans and difficulty in enrollment.
What about the effect of prior or concomitant treatment with an inhaled corticosteroid (ICS) on salmeterol treatment outcomes? This is how salmeterol is currently used according to guidelines. As the study authors said " SMART was not adequate to determine whether or not ICS use affected the incidence of the key outcome events."
To me, the most robust finding of SMART is that asthma treatment is much better when a patient in under a physcian's care than when a prescription is given to a patient and he is told that they will be contacted by phone to see how they are doing.
GSK was faced with the task of designing and executing a large clinical trial that had been brought about because of concern that salmeterol might be harmful to some patients with asthma. An earlier trial in Great Britain had shown a numerical increase in salmeterol treated patients that was not statistically significant. One lingering popular explanation for any possible increase in salmeterol treated patient death is that these patients were either under poor control at the beginning of the trial and/or perhaps used the medications improperly or inadequately.
So, what did they do?They recruited patients by advertisements, insuring a high proportion of patients who might not have been receiving good physician care, gave them either salmeterol or placebo and then provided only monthly telephone followup. At this point we have a group of patients, many of whom were not under good control or receiving regular physician hands-on follow up, who were given a medication that was purportedly possibly harmful and not monitored other than by telephone calls. They could not be accused of "cherry-picking" their study subjects in this trial.
This "phase one " recruitment ended when it appeared the trial would need over 60,000 participants (over twice what the original power computation indicated because of the relatively low mortality rate in both the control and treatment arms) and the recruitment process shifted to study investigators who recruited their own patients.This change brought about a situation at least resembling how the drug might be used in clinical practice.
There was a marked difference in the outcomes based on the method of recruitment. 13 of the 16 asthma related deaths occurred in patients recruited in phase one ( figure 2 in the SMART article in CHEST).There were about 15,00 patients in phase one versus about 11,000 in phase
2. The report's table 7 indicates that there were no statistically significant differences between salmeterol and placebo in any of the primary or secondary outcome measures in the phase 2 patients.
If there had been no phase 1 recruitment, there would likely be no black box warning on salmeterol containing products. It should be noted that this trial was terminated early by GSK. Only half of the subjects had been enrolled and the predefined criteria for terminations had not been met.The reasons given were the disproportionate number of events in African Americans and difficulty in enrollment.
What about the effect of prior or concomitant treatment with an inhaled corticosteroid (ICS) on salmeterol treatment outcomes? This is how salmeterol is currently used according to guidelines. As the study authors said " SMART was not adequate to determine whether or not ICS use affected the incidence of the key outcome events."
To me, the most robust finding of SMART is that asthma treatment is much better when a patient in under a physcian's care than when a prescription is given to a patient and he is told that they will be contacted by phone to see how they are doing.
Monday, June 12, 2006
Will a recent Meta-analysis be the tipping point to remove LABAs from the market?
Long acting bronchodilators (LABAs) have long been accused of increasing the number of asthma related deaths. My 12/23/2005 posting gave a brief summary of events up to that time.
Concern about LABAs was exacerbated by two studies that lead the FDA to issue a black box warning in November 2004.
A 16 week study from Great Britain, the Salmeterol National Surveillance Study (SNS) of 25,180 patients, found 12 deaths in the salmeterol group versus 2 in the placebo group a finding that was obviously numerically greater but not statistically significant.
Of greater concern was the SMART trial. This was a 28 week trial with 26,350 patients which demonstrated a 4.3 fold increase in asthma related deaths,( 13 versus 3) in the salmeterol treated group.
At least one important piece of information was not available from SMART. In the FDA statement we find this statement:
"The data from the SMART trial was not adequate to determine whether concurrent use of inhaled corticosteroids provides protection from this risk."
We really need to know if inhaled steroids mitigate or eliminate the putative increased risk from LABAs.Current recommendations essentially depend on that as the recommendation is to not start a LABA for asthma treatment until the patient is receiving at least moderate doses of steroids.
A recent meta-analysis published in the Annals of Internal Medicine seems to provide that missing information. Dr. Shelley R. Salpeter et al pooled results from 19 trials with 33,826 patients and found that LABAs ( not just salmeterol) increased exacerbations requiring hospitalizations (O.R. 2.6) and asthma related deaths (O.R.3.5). When the authors looked at the trials in which more than 75% of the participants were taking inhaled corticosteroids, the O.R. for hospitalizations was still increased at 2.1 ( 1.3 - 3.4).
While this may not be a slam dunk to answer all we need to know or to settle the issue, it is bound to raise the level of concern to a higher notch. Unfortunately, the authors do not give us more information about that part of their analysis nor do they include it in their article summary.However, in their concluding paragraph they say : " Concomitant inhaled corticosteroids do not adequately protect against adverse effects "
The LABA controversy will not be settled by this meta-analysis. A recent article from Australia quotes a Cochrane systematic review of LABA use in asthma and concludes they are safe and effective. As the editorial in the Annals noted, Evidence Based Medicine exhorts us to use the best evidence. Determining what is best sometimes is no easy matter. The medical literature dealing with the long acting beta agonists is extensive and replete with contradictory data. Since deaths from asthma are relatively uncommon, many physicians who use Advair and other LABA containing medications have not seen serious complications in their patients and typically observe better control in those patients requiring LABAs. It is not surprising that-as noted in the Salpeter article-the Black Box warning has not altered physicians's prescribing habits. Whether those habits should be changed or not seems to still be an open question.
Concern about LABAs was exacerbated by two studies that lead the FDA to issue a black box warning in November 2004.
A 16 week study from Great Britain, the Salmeterol National Surveillance Study (SNS) of 25,180 patients, found 12 deaths in the salmeterol group versus 2 in the placebo group a finding that was obviously numerically greater but not statistically significant.
Of greater concern was the SMART trial. This was a 28 week trial with 26,350 patients which demonstrated a 4.3 fold increase in asthma related deaths,( 13 versus 3) in the salmeterol treated group.
At least one important piece of information was not available from SMART. In the FDA statement we find this statement:
"The data from the SMART trial was not adequate to determine whether concurrent use of inhaled corticosteroids provides protection from this risk."
We really need to know if inhaled steroids mitigate or eliminate the putative increased risk from LABAs.Current recommendations essentially depend on that as the recommendation is to not start a LABA for asthma treatment until the patient is receiving at least moderate doses of steroids.
A recent meta-analysis published in the Annals of Internal Medicine seems to provide that missing information. Dr. Shelley R. Salpeter et al pooled results from 19 trials with 33,826 patients and found that LABAs ( not just salmeterol) increased exacerbations requiring hospitalizations (O.R. 2.6) and asthma related deaths (O.R.3.5). When the authors looked at the trials in which more than 75% of the participants were taking inhaled corticosteroids, the O.R. for hospitalizations was still increased at 2.1 ( 1.3 - 3.4).
While this may not be a slam dunk to answer all we need to know or to settle the issue, it is bound to raise the level of concern to a higher notch. Unfortunately, the authors do not give us more information about that part of their analysis nor do they include it in their article summary.However, in their concluding paragraph they say : " Concomitant inhaled corticosteroids do not adequately protect against adverse effects "
The LABA controversy will not be settled by this meta-analysis. A recent article from Australia quotes a Cochrane systematic review of LABA use in asthma and concludes they are safe and effective. As the editorial in the Annals noted, Evidence Based Medicine exhorts us to use the best evidence. Determining what is best sometimes is no easy matter. The medical literature dealing with the long acting beta agonists is extensive and replete with contradictory data. Since deaths from asthma are relatively uncommon, many physicians who use Advair and other LABA containing medications have not seen serious complications in their patients and typically observe better control in those patients requiring LABAs. It is not surprising that-as noted in the Salpeter article-the Black Box warning has not altered physicians's prescribing habits. Whether those habits should be changed or not seems to still be an open question.
Wednesday, June 07, 2006
Growing consensus not to use beta-blockers as initial choice for blood pressure treatment
Fueled largely by the results of the blood pressure arm of ASCOT, various authoritative medical organizations are demoting beta-blockers (BBs) from their former role as first line treatment for elevated blood pressure. NICE (the British National institute for Health and Clinical Excellence) and the British Hypertension Society have recently published guidelines that recommend BBs not be used as first line BP treatment except in cases of angina and HBP or in patients with excessive sympathetic tone or if they cannot tolerate ACEs or ARBs. They also recommend that if a patient is already on beta-blockers and a second BP drug is needed that the additional drug not be a diuretic because of the increased risk of diabetes.(Apparently the argument that since an increased mortality was not seen in ALLHAT patients who developed diabetes it is somehow OK if some medications trigger diabetes did not have much credence with the panel)
For those of us enamored by pathophysiology I refer back to a earlier posting that briefly reviewed data suggesting that beta-blockers are not as good as we once thought because-at least in part- of their failure to lower the central blood pressure while the ACEs and ARBs do.
For those of us enamored by pathophysiology I refer back to a earlier posting that briefly reviewed data suggesting that beta-blockers are not as good as we once thought because-at least in part- of their failure to lower the central blood pressure while the ACEs and ARBs do.
Saturday, June 03, 2006
A nap and a cup of coffee-What a concept.
I have posted before on the excessive sleepiness awareness "educational" programs that are appearing on the free doctor dinner programs and in various publications, there was a interesting juxtaposition of reading material arriving in my mail box.
The Annals of Internal Medicine ( June 6, 2006 issue) featured two articles on the effect of naps and coffee on "real life" situations and an editorial (" Naps and Drugs to Combat Fatigue and Sleepiness") by a well known and prolific sleep researcher, Dr. Christian Guilleminault. ( Annals Internal Medicine-volume 144,number 11 p. 856)
The other was a special issue of Internal Medicine World Report on the topic of excessive Sleepiness (ES). (ES has joined the ranks of conditions designated by an abbreviation and may soon rival ED in the level of promotional material produced.) The Report offered free CME and the authors credited with its material were an academic family doctor teamed with PhD sleep researcher from University of Michigan. The readers are told that the supplement was provided by "CME Outfitters,LLC" and was supported by an educational grant from Cephalon, Inc.,the manufacturer of modafinil (trade name Provigil).
The readers of the supplement are told that in order to accurately diagnose ES a detailed sleep history is necessary. A 14 item list of questions is suggested and the readers are told that it is critical to ask patients about the quality and quantity of sleep. It seems that ES is not only wide spread but it is said to be under recognized so we should seek it out in our patients.The list of "alertness-promoting agents" is reviewed and not surprisingly modafinil seems to be the best choice.
One of the Annals' article dealt with nighttime driving and demonstrated that either a nap or a caffeine containing beverage reduced the number of impaired driving events.A study involving interns showed that naps lead to less sensation of fatigue. Both sets of results conform with common sense and everyday experience (and with references noted in the articles and the editorial) and neither seems particularly monumental and I cannot help but wonder if this was a slow news day at the Annals editorial offices.
I found one of Dr. Guilleminault's editorial comments thought provoking. Apparently some of the interns did not really nap during their nap time.Some worked on the charts and others continued to take call for their own patients. He says :
"Clearly a 'medical culture element' (responsibility for one's own patients) was conflicting with the napping concept." He continues, " Perhaps it is time for medical housestaff to give the same weight to their responsibility to be alert as they do to their responsibility to be available to their patients.".
I will need more time to mull that over. I thought being responsible for your patients was a good thing.
The editorial is supportive of the use of napping and coffee to battle fatigue and sleepiness and is less enthusiastic about modafinil "The shortcomings of modafinil raise questions about the use of pharmacologic agents..."
Those comments are not surprising as a NEJM article and editorial last year seemed to indicate that modafinil was about as good as a big dose of coffee.
The Annals of Internal Medicine ( June 6, 2006 issue) featured two articles on the effect of naps and coffee on "real life" situations and an editorial (" Naps and Drugs to Combat Fatigue and Sleepiness") by a well known and prolific sleep researcher, Dr. Christian Guilleminault. ( Annals Internal Medicine-volume 144,number 11 p. 856)
The other was a special issue of Internal Medicine World Report on the topic of excessive Sleepiness (ES). (ES has joined the ranks of conditions designated by an abbreviation and may soon rival ED in the level of promotional material produced.) The Report offered free CME and the authors credited with its material were an academic family doctor teamed with PhD sleep researcher from University of Michigan. The readers are told that the supplement was provided by "CME Outfitters,LLC" and was supported by an educational grant from Cephalon, Inc.,the manufacturer of modafinil (trade name Provigil).
The readers of the supplement are told that in order to accurately diagnose ES a detailed sleep history is necessary. A 14 item list of questions is suggested and the readers are told that it is critical to ask patients about the quality and quantity of sleep. It seems that ES is not only wide spread but it is said to be under recognized so we should seek it out in our patients.The list of "alertness-promoting agents" is reviewed and not surprisingly modafinil seems to be the best choice.
One of the Annals' article dealt with nighttime driving and demonstrated that either a nap or a caffeine containing beverage reduced the number of impaired driving events.A study involving interns showed that naps lead to less sensation of fatigue. Both sets of results conform with common sense and everyday experience (and with references noted in the articles and the editorial) and neither seems particularly monumental and I cannot help but wonder if this was a slow news day at the Annals editorial offices.
I found one of Dr. Guilleminault's editorial comments thought provoking. Apparently some of the interns did not really nap during their nap time.Some worked on the charts and others continued to take call for their own patients. He says :
"Clearly a 'medical culture element' (responsibility for one's own patients) was conflicting with the napping concept." He continues, " Perhaps it is time for medical housestaff to give the same weight to their responsibility to be alert as they do to their responsibility to be available to their patients.".
I will need more time to mull that over. I thought being responsible for your patients was a good thing.
The editorial is supportive of the use of napping and coffee to battle fatigue and sleepiness and is less enthusiastic about modafinil "The shortcomings of modafinil raise questions about the use of pharmacologic agents..."
Those comments are not surprising as a NEJM article and editorial last year seemed to indicate that modafinil was about as good as a big dose of coffee.
Saturday, May 27, 2006
To see what P4P is really all about, look at the Seattle Blue Shield experience
The May 26, 2006 posting on Health Care Renewal references a news report on the "quality" and P4P acitvities in Seattle.
As critical as I have been on the P4P issue, the reality seems even worse. In this case, according to the news report,the carrier dropped about 500 physicians from their plans by a secret quality assesment process (using biling records apparently), and sent letters to 8,000 patients telling them their docs were delisted because of quality and efficiency issues.
As an aside I would like to know why this is not libel per se or at least ordinary libel.
But that is not my main point. The following is:
If the physicians who advocate accepting P4P such, as the leadership at ACP, believe that P4P is or will be about thoughtful, well intentioned physicians agreeing on scientifically established quality indicators and compliant physicians being rewarded for showing they comply with them, I cannot help but believe they are either naive or disingenuous.It will be and-as in the Seattle case- already is about saving money and controlling physicians.
It was about a year ago that I blogged about the egregious "performance" program initiated by United Health Group in St. Louis. That program also had no resemblance to the features of a "good " P4P program that the AMA envisioned and was harmful to physicans and patients alike.
Physician groups who advocate P4P argue that if we do not work with the third parties to make the rules, all the rules will be made by them. The Seattle and St. Louis experience-as well as the entire managed care saga-tell us clearly the third party payers will make all the rules anyway.
As critical as I have been on the P4P issue, the reality seems even worse. In this case, according to the news report,the carrier dropped about 500 physicians from their plans by a secret quality assesment process (using biling records apparently), and sent letters to 8,000 patients telling them their docs were delisted because of quality and efficiency issues.
As an aside I would like to know why this is not libel per se or at least ordinary libel.
But that is not my main point. The following is:
If the physicians who advocate accepting P4P such, as the leadership at ACP, believe that P4P is or will be about thoughtful, well intentioned physicians agreeing on scientifically established quality indicators and compliant physicians being rewarded for showing they comply with them, I cannot help but believe they are either naive or disingenuous.It will be and-as in the Seattle case- already is about saving money and controlling physicians.
It was about a year ago that I blogged about the egregious "performance" program initiated by United Health Group in St. Louis. That program also had no resemblance to the features of a "good " P4P program that the AMA envisioned and was harmful to physicans and patients alike.
Physician groups who advocate P4P argue that if we do not work with the third parties to make the rules, all the rules will be made by them. The Seattle and St. Louis experience-as well as the entire managed care saga-tell us clearly the third party payers will make all the rules anyway.
Thursday, May 25, 2006
Presumption seems to be Doctors will not do right by patients unless....
Dr. Philip R. Alper's "IM Insights" appearing in "Internal Medicine World Report" monthly continue to be packed with insights born of thoughtful consideration of years of experience. In the April 2006 issue, he discusses " Will the Real Patient Advocate Please Step Forward?"
He recalls from his days of Internal Medicine training in the 60's that the internist was the person who provided "effective and comprehensive patient advocacy that activity being a "cardinal characteristic that set internists apart". Now it seems that numerous voices are telling us that decisions about care that may have previously been a joint effort made the physician and the patient are too important and too likely to be handled badly by the physician to be left in their hands alone.
Now, that advocacy role is being eroded away by several forces, one of which is the multiplicity of entities that all proclaim the need for such advocacy and self proclaim that role for themselves. In the rhetoric of many such advocates the presumption has become "The doctor will not do right by the patient unless other agents intervene "
Who are these advocates and what energizes their activities?
Well, almost everyone, but the most visible and vocal are :the Institute of Medicine,AARP,and the HMOs and insurance carriers and even the American College of Physicians but motivations of various members of this diverse list are not all the same.
Alper asserts that a " kind of blame game " is being played by the carriers.When their,at times, blatant denials of care evoked the ire of the public they backed off a bit shifting to more patient cost-sharing and blaming the high cost of medical care on "poor quality". Patients were not getting good value for their money and of course it is the physician who largely provides that care.It would follow that someone must oversee and manage the physician's care because left to their own devices docs will crank out poor value care.Audits, guidelines,pay for performance (tipping the docs for doing a good job)are,in this view, necessary to protect the patients from the default position of poor quality which physicians typically deliver unless third parties intervene to protect the patient.
Managed Care is a major force in all of this on several levels.On a practical level the time crunch physicians face leaves little time to be an advocate in many situations.More broadly, Managed Care's "quality movement" may well function as a more sophisticated "denial of care"-saving money under the rubric of convincing everyone they are improving care.
The model of independent individual physicians providing care to individual patients is antithetical to those who are strong advocates of a single payer system.A quality gap is a concept they might embrace. A crisis is great opportunity to bring about change.
There are many thoughtful,dedicated physicians who sincerely want to improve care to patients and whose motivations are not those of the insurance carriers which is to save money. There are many aspects of medical care in this country ( and every country) that could and should be improved. Working to do that is not always motivated by the cost containment model but at least some of the rhetoric of "patient advocacy" and "quality" is motivated by exactly that desire. Also, some of that rhetoric is driven by a desire -for whatever reasons- to replace what remnants of fee-for- service medical care by independent physicians still exist with a system less sympathetic to the individual and more attuned to notions of social justice and public health.
How did a profession historically dedicated to the premise of doing the right thing for the patient find itself constantly apologizing for what it does and being blamed largely for being responsible for what is being characterized as crisis in care? Why are we accepting that blame? Why do we not hear of a crisis in legal representation, in the services rendered by architects,contractors, or even car salesman and roofing companies?
He recalls from his days of Internal Medicine training in the 60's that the internist was the person who provided "effective and comprehensive patient advocacy that activity being a "cardinal characteristic that set internists apart". Now it seems that numerous voices are telling us that decisions about care that may have previously been a joint effort made the physician and the patient are too important and too likely to be handled badly by the physician to be left in their hands alone.
Now, that advocacy role is being eroded away by several forces, one of which is the multiplicity of entities that all proclaim the need for such advocacy and self proclaim that role for themselves. In the rhetoric of many such advocates the presumption has become "The doctor will not do right by the patient unless other agents intervene "
Who are these advocates and what energizes their activities?
Well, almost everyone, but the most visible and vocal are :the Institute of Medicine,AARP,and the HMOs and insurance carriers and even the American College of Physicians but motivations of various members of this diverse list are not all the same.
Alper asserts that a " kind of blame game " is being played by the carriers.When their,at times, blatant denials of care evoked the ire of the public they backed off a bit shifting to more patient cost-sharing and blaming the high cost of medical care on "poor quality". Patients were not getting good value for their money and of course it is the physician who largely provides that care.It would follow that someone must oversee and manage the physician's care because left to their own devices docs will crank out poor value care.Audits, guidelines,pay for performance (tipping the docs for doing a good job)are,in this view, necessary to protect the patients from the default position of poor quality which physicians typically deliver unless third parties intervene to protect the patient.
Managed Care is a major force in all of this on several levels.On a practical level the time crunch physicians face leaves little time to be an advocate in many situations.More broadly, Managed Care's "quality movement" may well function as a more sophisticated "denial of care"-saving money under the rubric of convincing everyone they are improving care.
The model of independent individual physicians providing care to individual patients is antithetical to those who are strong advocates of a single payer system.A quality gap is a concept they might embrace. A crisis is great opportunity to bring about change.
There are many thoughtful,dedicated physicians who sincerely want to improve care to patients and whose motivations are not those of the insurance carriers which is to save money. There are many aspects of medical care in this country ( and every country) that could and should be improved. Working to do that is not always motivated by the cost containment model but at least some of the rhetoric of "patient advocacy" and "quality" is motivated by exactly that desire. Also, some of that rhetoric is driven by a desire -for whatever reasons- to replace what remnants of fee-for- service medical care by independent physicians still exist with a system less sympathetic to the individual and more attuned to notions of social justice and public health.
How did a profession historically dedicated to the premise of doing the right thing for the patient find itself constantly apologizing for what it does and being blamed largely for being responsible for what is being characterized as crisis in care? Why are we accepting that blame? Why do we not hear of a crisis in legal representation, in the services rendered by architects,contractors, or even car salesman and roofing companies?
Monday, May 22, 2006
According to ACP, Quality initiatives takes time and money and (so far) no reimbursement
The ACP observer-an American College of Physician's monthly newspaper format publication- has a section called "Measuring Performance"
The May 2,2006 presents the reader with anecdotal material about several internists' efforts to "close [various] quality gaps".
One internist is said to have spent an estimated $15,000 to increase the number of her diabetic patients getting the recommended annual ophthalmologist eye exam. They finally "solved" the problem (at the beginning only 35% of her patients received the exam annually) by having her office call the eye doc's office and make appointments for all 2,000 of her diabetic patients. At 15 k per project you have to wonder how much quality this physician can afford while waiting for the P4W repayment for her efforts down the road.
Other physicians' efforts are described in the article including the experience of one physician whose practice not only had to foot the increased overhead bill(s) of quality project(s) but two physicians left the practice because they were unwilling to accept the higher costs of running the practice.
The quality issues described in this article and the ones often discussed seem to be those related to patient compliance,for example, patients taking their aspirin everyday, patients getting their colon cancer screening, etc. I have a problem accepting the concept that there is a quality problem with physician's care in the circumstance wherein the patient -for whatever reason-does not comply with the advice. How far does one have to go to maximize compliance? Is there at some point a tension with the concept of patient autonomy and respect for patient's decisions? Do patients have to be monitored like children to be sure they are taking their vitamins ? Are we moving towards a version of extreme "paternalism", with a new twist -the twist being -"not only do we know what is best for you we going to check up on you to make sure you do it?
The article says "Until reimbursement becomes a reality,quality improvement efforts can cost more that they can yield financially" As CMS and third party payers continue to decrease reimbursements,ACP's solution,in part, seems to be to encourage internists to spend money on quality projects that may be reimbursed someday and for which we still await evidence that it all will really improve patient care.
The "lets narrow the quality gaps" movements is part of the ACP's scheme to salvage internal medicine. Their own publication's article about the grass root efforts along those lines is more likely to discourage than energize private doctors to join the effort. Bottom line losses have to impact decisions. On a more fundamental level, I believe labeling these simplistic projects based on some organization's arbitrary "quality target" as improving quality is flawed. The author quotes a IM residency quality project involving encouraging diabetic patients to have an annual foot exam involving in part having "a colorful brochure in the waiting room with tips of what to ask the doctor".
I cannot help but remember when being an internist was more about having the skills and dedication to take care of patients with complex (and simple) medical problems than having colorful brochures in the office exhorting patients to do the preventive medicine measure of the day.
The May 2,2006 presents the reader with anecdotal material about several internists' efforts to "close [various] quality gaps".
One internist is said to have spent an estimated $15,000 to increase the number of her diabetic patients getting the recommended annual ophthalmologist eye exam. They finally "solved" the problem (at the beginning only 35% of her patients received the exam annually) by having her office call the eye doc's office and make appointments for all 2,000 of her diabetic patients. At 15 k per project you have to wonder how much quality this physician can afford while waiting for the P4W repayment for her efforts down the road.
Other physicians' efforts are described in the article including the experience of one physician whose practice not only had to foot the increased overhead bill(s) of quality project(s) but two physicians left the practice because they were unwilling to accept the higher costs of running the practice.
The quality issues described in this article and the ones often discussed seem to be those related to patient compliance,for example, patients taking their aspirin everyday, patients getting their colon cancer screening, etc. I have a problem accepting the concept that there is a quality problem with physician's care in the circumstance wherein the patient -for whatever reason-does not comply with the advice. How far does one have to go to maximize compliance? Is there at some point a tension with the concept of patient autonomy and respect for patient's decisions? Do patients have to be monitored like children to be sure they are taking their vitamins ? Are we moving towards a version of extreme "paternalism", with a new twist -the twist being -"not only do we know what is best for you we going to check up on you to make sure you do it?
The article says "Until reimbursement becomes a reality,quality improvement efforts can cost more that they can yield financially" As CMS and third party payers continue to decrease reimbursements,ACP's solution,in part, seems to be to encourage internists to spend money on quality projects that may be reimbursed someday and for which we still await evidence that it all will really improve patient care.
The "lets narrow the quality gaps" movements is part of the ACP's scheme to salvage internal medicine. Their own publication's article about the grass root efforts along those lines is more likely to discourage than energize private doctors to join the effort. Bottom line losses have to impact decisions. On a more fundamental level, I believe labeling these simplistic projects based on some organization's arbitrary "quality target" as improving quality is flawed. The author quotes a IM residency quality project involving encouraging diabetic patients to have an annual foot exam involving in part having "a colorful brochure in the waiting room with tips of what to ask the doctor".
I cannot help but remember when being an internist was more about having the skills and dedication to take care of patients with complex (and simple) medical problems than having colorful brochures in the office exhorting patients to do the preventive medicine measure of the day.
Thursday, May 18, 2006
'Other people's money" and the moral costs of managed care
Dr. Patricia Illingworth is an associate professor of philosophy at Northeastern University and holds a PhD and JD degree. Her writings express well the observations that are commonly made by physicians about the world in which they live and work which is dominated by managed care.
Medical care came to be "managed " by the managed care sector because of the concept of "other people's money". To a large degree individuals pay for only a portion of their health care the remainder paid by either employers or the government. There was little issue made by these other people until the costs of health care rose to some threshold above which employers and other third party payers including CMS thought costs were getting out of hand. Then entered cost containment via the various cost savings actions of managed care.
Dr. Illingworth believes that the modification of the traditional fiduciary duties of physicians to patients by the duties of the for-profit corporation vis-a -vis shareholders is the root cause of many ethical problems generated by managed care. Basically the HMO strives to make money or save it and they introduce mechanisms to control physician behavior to that end even if that control involves abrogation of the fundamental duty of the doctor to place the patient first. The efforts of the HMO in that regard weaken the physician-patient relationship and damage the trust element in the relationship.
In her recent book, Trusting Medicine: The Moral Costs of Managed Care she outlines her argument and it is reviewed in the May 10,2006 issue of JAMA. It is gratifying to read an academician express many of the same views you would hear in the doctor's lounge at your local hospital- that is if there still was such a place.
In a review of an article she wrote for Northeasten University Magazine she is quoted:
"Part of the problem is that some commonly accepted principles of business ethics are fundamentally incompatible with traditional medical ethics...
Dr. Illingworth says bluffing (holding back certain information), puffing (exaggerating) and spinning (putting the best face forward on undesirable outcomes) are part of normal day to day business practices but have no place in the physician-patient relationship where honest relationships are essential to good practice. However, physicians dependent upon managed care companies may be influenced and controlled to the extent that their behavior favors the company's bottom line more than the patient's interests in spite of the doctor's effort to swim against the tide.
As the reviewer in JAMA noted, President Bush listed as one of the goals for health care was to "strengthen the doctor-patient relationship". Has the doctor patient relationship eroded so badly that it deserves to be a topic in a State of the Union address ? Maybe so.The erosion of patient trust and the deterioration of the physician-patient relationship are, in my opinion, directly related to managed care. I do not see how the trend can be reversed as long as managed care companies continue to exert hegemony over physicians.
As is so many matters,I have no solution but I do not believe that as long as managed care entities exert their domination over practicing physicians that such things as electronic medical records, having docs audit themselves to see to what degree they adhere to selected guidelines and calling it all a "medical home" will restore the deteriorating doctor-patient relationship.
Medical care came to be "managed " by the managed care sector because of the concept of "other people's money". To a large degree individuals pay for only a portion of their health care the remainder paid by either employers or the government. There was little issue made by these other people until the costs of health care rose to some threshold above which employers and other third party payers including CMS thought costs were getting out of hand. Then entered cost containment via the various cost savings actions of managed care.
Dr. Illingworth believes that the modification of the traditional fiduciary duties of physicians to patients by the duties of the for-profit corporation vis-a -vis shareholders is the root cause of many ethical problems generated by managed care. Basically the HMO strives to make money or save it and they introduce mechanisms to control physician behavior to that end even if that control involves abrogation of the fundamental duty of the doctor to place the patient first. The efforts of the HMO in that regard weaken the physician-patient relationship and damage the trust element in the relationship.
In her recent book, Trusting Medicine: The Moral Costs of Managed Care she outlines her argument and it is reviewed in the May 10,2006 issue of JAMA. It is gratifying to read an academician express many of the same views you would hear in the doctor's lounge at your local hospital- that is if there still was such a place.
In a review of an article she wrote for Northeasten University Magazine she is quoted:
"Part of the problem is that some commonly accepted principles of business ethics are fundamentally incompatible with traditional medical ethics...
Dr. Illingworth says bluffing (holding back certain information), puffing (exaggerating) and spinning (putting the best face forward on undesirable outcomes) are part of normal day to day business practices but have no place in the physician-patient relationship where honest relationships are essential to good practice. However, physicians dependent upon managed care companies may be influenced and controlled to the extent that their behavior favors the company's bottom line more than the patient's interests in spite of the doctor's effort to swim against the tide.
As the reviewer in JAMA noted, President Bush listed as one of the goals for health care was to "strengthen the doctor-patient relationship". Has the doctor patient relationship eroded so badly that it deserves to be a topic in a State of the Union address ? Maybe so.The erosion of patient trust and the deterioration of the physician-patient relationship are, in my opinion, directly related to managed care. I do not see how the trend can be reversed as long as managed care companies continue to exert hegemony over physicians.
As is so many matters,I have no solution but I do not believe that as long as managed care entities exert their domination over practicing physicians that such things as electronic medical records, having docs audit themselves to see to what degree they adhere to selected guidelines and calling it all a "medical home" will restore the deteriorating doctor-patient relationship.
Wednesday, May 17, 2006
Economy Class syndrome and which of Virchow's mechanism (s) may be to blame
A recent JAMA article (the full text is available on line) from Great Britain sheds some light on possible mechanism (s) involved in the development of venous thrombosis in long haul air travelers. ( Long haul is usually taken to mean 8 hours or more.)It does this by failing to demonstrate evidence for an increased tendency of the blood to clot after doing extensive testing for relevant blood coagulation system changes including tests for platelet activation,fibrinolysis,and coagulation factor activation.
The issue-in part- has been if the reported association between long haul flights and venous thromboembolism (VTE) is due to prolonged sitting -at times in cramped conditions- or does the air travel induce some increased tendency to clot perhaps related to hypoxia and or decreased atmospheric pressure ( hypobaria) and , of course, both could be operative.
This study simulated air travel using a hypobaric chamber to expose some 73 healthy volunteers to hypobaric hypoxia for 8 hours Persons with either the prothrombin gene mutation (G200210A) or Factor V Leiden were excluded. The study design compared sitting for 8 hours with and without the impositions of hypoxic hypobaric conditions. No significant differences in the various tests of the clotting system were found.
It seems that every talk on VTE has ( or at least used to have) an obligatory introductory section mentioning Virchow's triad of possible culprits predisposing to thrombosis; 1) damage to the vessel wall, 2) alterations in blood flow (stasis or turbulent flow) and 3) increased tendency of the blood to clot. This paper goes at least part of the way to shift the blame in economy class syndrome to the second category. This should encourage travelers to move around as much as possible on the long flights and might be a disincentive to take a sleeping pill and sleep for much of the flight. The rest of the current advice package-at least for persons at no known increased VTE risk is to keep well hydrated and avoid alcohol. Persons recognized to be at higher risk should use graduated pressure stockings and consider low molecular weight heparin pre flight depending on the level of perceived increased risk (such as those with a history of VTE).
It should be noted that persons with Factor V Leiden and or the prothrombin mutation represent a different situation.The editorial in the same issue of JAMA noted that some evidence of hypercoagulability has been noted in persons with those two inherited conditions with exposure to flight conditions. Whether they should be offered low molecular weight heparin is an issue about which experts differ.
The issue-in part- has been if the reported association between long haul flights and venous thromboembolism (VTE) is due to prolonged sitting -at times in cramped conditions- or does the air travel induce some increased tendency to clot perhaps related to hypoxia and or decreased atmospheric pressure ( hypobaria) and , of course, both could be operative.
This study simulated air travel using a hypobaric chamber to expose some 73 healthy volunteers to hypobaric hypoxia for 8 hours Persons with either the prothrombin gene mutation (G200210A) or Factor V Leiden were excluded. The study design compared sitting for 8 hours with and without the impositions of hypoxic hypobaric conditions. No significant differences in the various tests of the clotting system were found.
It seems that every talk on VTE has ( or at least used to have) an obligatory introductory section mentioning Virchow's triad of possible culprits predisposing to thrombosis; 1) damage to the vessel wall, 2) alterations in blood flow (stasis or turbulent flow) and 3) increased tendency of the blood to clot. This paper goes at least part of the way to shift the blame in economy class syndrome to the second category. This should encourage travelers to move around as much as possible on the long flights and might be a disincentive to take a sleeping pill and sleep for much of the flight. The rest of the current advice package-at least for persons at no known increased VTE risk is to keep well hydrated and avoid alcohol. Persons recognized to be at higher risk should use graduated pressure stockings and consider low molecular weight heparin pre flight depending on the level of perceived increased risk (such as those with a history of VTE).
It should be noted that persons with Factor V Leiden and or the prothrombin mutation represent a different situation.The editorial in the same issue of JAMA noted that some evidence of hypercoagulability has been noted in persons with those two inherited conditions with exposure to flight conditions. Whether they should be offered low molecular weight heparin is an issue about which experts differ.
Tuesday, May 09, 2006
How drug companies know what physicians prescribe
It seems to be common knowledge among practicing physicians that the drug reps know who prescribes what.That type information is thought to be important to big pharma marketing activities. However, I was ignorant about how all this works.
The Blog that Ate Mahattan (TBTAM) explains it and references an article in the NYT.
It seems that drug store chains sell that information to various data gathering companies that then merge the data with the AMA's physician masterfile. This the file that is generated by rank and file docs across the country filling out the AMA's form. The AMA sells this information to various entities including database companies that supply the info to drug companies so that the drug rep knows if you are really using whatever drug.
There are legitimate uses for the AMA data base base. For example, the black box "dear doctor" letters sent out by drug companies to warn of side effects or recalls uses this information. However, providing data about individual doctor prescribing habits to drug companies is not a legitimate use.
Go to TBTAM to learn how to achieve a limited opt- out of the drug reps prying into your business. The AMA is getting some deserved flak for this activity and they are trying to placate docs and still maintain their lucrative data selling business.
The Blog that Ate Mahattan (TBTAM) explains it and references an article in the NYT.
It seems that drug store chains sell that information to various data gathering companies that then merge the data with the AMA's physician masterfile. This the file that is generated by rank and file docs across the country filling out the AMA's form. The AMA sells this information to various entities including database companies that supply the info to drug companies so that the drug rep knows if you are really using whatever drug.
There are legitimate uses for the AMA data base base. For example, the black box "dear doctor" letters sent out by drug companies to warn of side effects or recalls uses this information. However, providing data about individual doctor prescribing habits to drug companies is not a legitimate use.
Go to TBTAM to learn how to achieve a limited opt- out of the drug reps prying into your business. The AMA is getting some deserved flak for this activity and they are trying to placate docs and still maintain their lucrative data selling business.
Sunday, May 07, 2006
Devotion,curiosity, hard work and the Midnight Meal
JAMA has reviewed a book that would probably interest senior docs who trained in the 60' and 70's particularly at a big city hospital. According to the review there is plenty of interest for younger one as well. The book is The Midnight Meal and other Essays about Doctors, Patients and Medicine by Jerome Lowenstein,an internist who trained at Bellevue and stayed on to teach there.I like to think that thoughtful physicians who have been doing it for 30 years or more have something to offer. His comments do.
I took my pulmonary boards at Bellevue (back when it was an oral exam) and much he has to say resonates with my memories of another big city hospital, Charity in New Orleans.
In his section on
"Can you teach compassion? ", he writes
"...teachers in medicine can only hope to facilitate the development of students or young physicians,challenging and stimulating them and acting as role models."
I know much of my development was influenced by role models.I can still remember much about those physicians in surprising detail many years later. The passage of time has made it very clear to me how important those role models were
The reviewer says " Devotion, curiosity and hard work were the messages of these teachers"
The messages I got from my role models also included respect for the patient,duty to do what was right for the patient,the obligation to know as much as you could because that may actually save a life or mitigate an illness's effect.There was no message sent about going home at five o'clock and leaving the problems to some one else.
The "midnight meal" part of the book's title refers to a meal, leftovers mainly, served late at night to the docs on call.Charity Hosptial did that as well-we called it "Late Doctors" It was a good time to catch consultants (our paging system left a little to be desired). The late meal was often the highlight of a night on call. It seemed that way at the time but the real highlight was the incredible and intense opportunity to learn how to be a physician by taking care of real patients often late into the night under the tutorage of more senior (sometimes only by a year or so) physicians.
I took my pulmonary boards at Bellevue (back when it was an oral exam) and much he has to say resonates with my memories of another big city hospital, Charity in New Orleans.
In his section on
"Can you teach compassion? ", he writes
"...teachers in medicine can only hope to facilitate the development of students or young physicians,challenging and stimulating them and acting as role models."
I know much of my development was influenced by role models.I can still remember much about those physicians in surprising detail many years later. The passage of time has made it very clear to me how important those role models were
The reviewer says " Devotion, curiosity and hard work were the messages of these teachers"
The messages I got from my role models also included respect for the patient,duty to do what was right for the patient,the obligation to know as much as you could because that may actually save a life or mitigate an illness's effect.There was no message sent about going home at five o'clock and leaving the problems to some one else.
The "midnight meal" part of the book's title refers to a meal, leftovers mainly, served late at night to the docs on call.Charity Hosptial did that as well-we called it "Late Doctors" It was a good time to catch consultants (our paging system left a little to be desired). The late meal was often the highlight of a night on call. It seemed that way at the time but the real highlight was the incredible and intense opportunity to learn how to be a physician by taking care of real patients often late into the night under the tutorage of more senior (sometimes only by a year or so) physicians.
Friday, May 05, 2006
JAMA reviews book on clinical judgment-"phronesis"
There is a favorable book review in the May 3,2006 issue of JAMA regarding what seems to be a very interesting book titled How Doctors Think: Clinical Judgment and the Practice of Medicine by Kathryn Montgomery. Dr. Montgomery is a professor of bioethics and medical humanities at Northwestern University.
One of her main themes is that clinical medicine is not a science.Even though I wonder if that statement is a straw man (I have always considered science as only part of medical practice as is implied when we talk about about the art and the science of medicine),there are a number of insights quoted in the review-enough to motivate me to order the book.
I quote from the review:
"Rather than considering medicine a science,she proposes that it be conceptualized as a rational,science-using practice.She draws on phronesis-the flexible interpretive capacity that enables moral reasoners to determine the best action to take when knowledge depends on circumstances-to characterize physician thinking in the clinical encounter as interpretive practice. In clinical medicine, this interpretive practice is displayed as clinical judgment which enables physicians to combine scientific information,clinical skill, and collective experience with similar patients to make sense of the particulars of one patient's illness and to determine the best action to take to cure of alleviate it."
"Clinical judgment done well is the intuitive and iterative negotiation of the patient's narrative of illness...This focus come with experience"
Aristotle spoke of the virtues of the ordered mind as including sophia (wisdom of first principles),episteme (emperical knowledge, techne (technical knowledge) nous (intuition) and phronesis (practical wisdom or prudence).
The evidence based medicine era with its emphatic focus on episteme and techne may foster the illusion that good clinical practice can be encapsulated in guidelines and pathways and that quality lies in obedience to them but it is the blending of those elements of science and technique with practical wisdom that makes good practice.
While Aristotle may have been bit harsh on the young the following quote captures the thought well that the particulars must sharpen the broad outline and abstractions of the "universals" that might correspond to the general clinical rules or guidelines and give them operational meaning tailored to the facts at hand:
"Whereas young people become accomplished in geometry and mathematics, and wise within these limits, prudent young people do not seem to be found. The reason is that prudence is concerned with particulars as well as universals, and particulars become known from experience but young person lacks experience, since some length of time is needed to produce it."
(Nichomachean Ethics)
One of her main themes is that clinical medicine is not a science.Even though I wonder if that statement is a straw man (I have always considered science as only part of medical practice as is implied when we talk about about the art and the science of medicine),there are a number of insights quoted in the review-enough to motivate me to order the book.
I quote from the review:
"Rather than considering medicine a science,she proposes that it be conceptualized as a rational,science-using practice.She draws on phronesis-the flexible interpretive capacity that enables moral reasoners to determine the best action to take when knowledge depends on circumstances-to characterize physician thinking in the clinical encounter as interpretive practice. In clinical medicine, this interpretive practice is displayed as clinical judgment which enables physicians to combine scientific information,clinical skill, and collective experience with similar patients to make sense of the particulars of one patient's illness and to determine the best action to take to cure of alleviate it."
"Clinical judgment done well is the intuitive and iterative negotiation of the patient's narrative of illness...This focus come with experience"
Aristotle spoke of the virtues of the ordered mind as including sophia (wisdom of first principles),episteme (emperical knowledge, techne (technical knowledge) nous (intuition) and phronesis (practical wisdom or prudence).
The evidence based medicine era with its emphatic focus on episteme and techne may foster the illusion that good clinical practice can be encapsulated in guidelines and pathways and that quality lies in obedience to them but it is the blending of those elements of science and technique with practical wisdom that makes good practice.
While Aristotle may have been bit harsh on the young the following quote captures the thought well that the particulars must sharpen the broad outline and abstractions of the "universals" that might correspond to the general clinical rules or guidelines and give them operational meaning tailored to the facts at hand:
"Whereas young people become accomplished in geometry and mathematics, and wise within these limits, prudent young people do not seem to be found. The reason is that prudence is concerned with particulars as well as universals, and particulars become known from experience but young person lacks experience, since some length of time is needed to produce it."
(Nichomachean Ethics)
Wednesday, May 03, 2006
Another reason to distrust company sponsored drug trials-fraud
Health Care Renewal in its May 3,2006 posting quotes a Wall Street Journal article that reveals alarming information about one drug trial involving telithromycin(Ketex),a macrolide antibiotic recently incriminated in causing serious liver toxicity and one that has been heavily promoted in various free "educational" publications and talks by infectious disease "thought leaders".
Physicians have probably to some degree become accustomed to looking more carefully at drug trials-when they have time to do it-to watch out for the usual bag of tricks, such as comparing the highlighted drug with an inadequate dose of a comparator drug. However, presenting outright bogus data-such as fabricated "patients" is a different level of egregious behavior.
HCR calls attention to the role of a contractor company,Pharmaceutical Product Development,INC (PPD) that facilitates and organizes -among other things-drug treatment trials as the most blatant culprits in this saga were private practice docs.
The story in a nutshell is that at least two of the private physicians taking part in the trial apparently fabricated data. Questions arise regarding the adequacy of oversight by both PPD and the contracting Big Pharma company, Sanofi-Aventis and the FDA conduct in the approval process will likely generate criticism as well. One of the doctors who ran a weight control practice somehow managed to enroll 30 new patients a day (the patients were supposed to have a respiratory tract infection requiring antibiotic therapy).The physician was subsequently convicted of mail fraud in regard to her activities in this trial.
As the investigation unfolds we will likely hear from both PPD and Sanofi-Aventis that they did everything according to the usual rules of research conduct but the bottom line seems to be that a drug was approved by the FDA and data from a very flawed trial may have been used to attest to its safety.
Randomized clinical trials (RCT) may be able to serve us well in the setting of determining the efficacy of a drug but the label of RCT on a publication does not tell us anything about the integrity of the data which in this case seems corrupted by fabrication. Fraud, lying and cheating may be harder to detect than statistical slanting of the data.
To me,the worse part of this sad story is that the most flagrant behavior was exhibited by private practice doctors.
Physicians have probably to some degree become accustomed to looking more carefully at drug trials-when they have time to do it-to watch out for the usual bag of tricks, such as comparing the highlighted drug with an inadequate dose of a comparator drug. However, presenting outright bogus data-such as fabricated "patients" is a different level of egregious behavior.
HCR calls attention to the role of a contractor company,Pharmaceutical Product Development,INC (PPD) that facilitates and organizes -among other things-drug treatment trials as the most blatant culprits in this saga were private practice docs.
The story in a nutshell is that at least two of the private physicians taking part in the trial apparently fabricated data. Questions arise regarding the adequacy of oversight by both PPD and the contracting Big Pharma company, Sanofi-Aventis and the FDA conduct in the approval process will likely generate criticism as well. One of the doctors who ran a weight control practice somehow managed to enroll 30 new patients a day (the patients were supposed to have a respiratory tract infection requiring antibiotic therapy).The physician was subsequently convicted of mail fraud in regard to her activities in this trial.
As the investigation unfolds we will likely hear from both PPD and Sanofi-Aventis that they did everything according to the usual rules of research conduct but the bottom line seems to be that a drug was approved by the FDA and data from a very flawed trial may have been used to attest to its safety.
Randomized clinical trials (RCT) may be able to serve us well in the setting of determining the efficacy of a drug but the label of RCT on a publication does not tell us anything about the integrity of the data which in this case seems corrupted by fabrication. Fraud, lying and cheating may be harder to detect than statistical slanting of the data.
To me,the worse part of this sad story is that the most flagrant behavior was exhibited by private practice doctors.
Annals Internal Medicine letter" Seasoned internist blames Academic Medicine for much of internist's crisis
In the May 2, 2006 issue of the Annals of Internal Medicine, Dr. Ashok V. Daftary in a letter to the editor blames academic medicine for much in the unfolding saga for the demise of internal medicine.
He writes:
"Academic medicine is the carpenter that fashioned the coffin of internal medicine.Instead of reengineering internal medicine to accommodate changes, it cannibalized the discipline by reducing its worth, creating the hospitalist and ambulatory care internist. These were both nails that helped seal the coffin; the former reduced the influence of the internist in the acute care environment and the latter blurred distinctions between internists and those without medical degrees who practice in the ambulatory settings."
"...absent an identity, the internist's only remaining role is thought to be that of provider of ambulatory care to chronically ill whose medical problems are beyond procedural intervention and lucrative compensation."
I do not know the relative contributions of academia and managed care to the birth and growth of the hospitalist phenomenon but my default position is to always blame managed care. The "follow-the money" rule does not always lead to the right answer but that it where the smart money bets. I think at most some academic and "thought leader" internists were complicit.
I believe, though, that the recommendations to change the IM residency program to allow (or encourage?) the third year residents to opt to do more in patient or more out patient training-based on their future plans will only make worse the schism betweeen the hospital internist and the "officist" and do little to lessen the increasing fragmentation of medical care. And the idea that an IM resident could do the training, opt to be a office doctor and never -after the residency-take care of patients with complicated serious ilnesses in the hospital is so contrary to what a internist is (used to be ?) all about.
He writes:
"Academic medicine is the carpenter that fashioned the coffin of internal medicine.Instead of reengineering internal medicine to accommodate changes, it cannibalized the discipline by reducing its worth, creating the hospitalist and ambulatory care internist. These were both nails that helped seal the coffin; the former reduced the influence of the internist in the acute care environment and the latter blurred distinctions between internists and those without medical degrees who practice in the ambulatory settings."
"...absent an identity, the internist's only remaining role is thought to be that of provider of ambulatory care to chronically ill whose medical problems are beyond procedural intervention and lucrative compensation."
I do not know the relative contributions of academia and managed care to the birth and growth of the hospitalist phenomenon but my default position is to always blame managed care. The "follow-the money" rule does not always lead to the right answer but that it where the smart money bets. I think at most some academic and "thought leader" internists were complicit.
I believe, though, that the recommendations to change the IM residency program to allow (or encourage?) the third year residents to opt to do more in patient or more out patient training-based on their future plans will only make worse the schism betweeen the hospital internist and the "officist" and do little to lessen the increasing fragmentation of medical care. And the idea that an IM resident could do the training, opt to be a office doctor and never -after the residency-take care of patients with complicated serious ilnesses in the hospital is so contrary to what a internist is (used to be ?) all about.
Friday, April 28, 2006
Australian study demonstrates calcium only works if you take the pills.
The April 24, 2006 issue of the Archives of Internal Medicine published a study from Australia that examined the effects of a twice daily supplement of 600 mg. of calcium carbonate on fracture rates and bone density.
This was a 5 year, double blind, placebo-controlled trial of 1660 women older than 70 years of age.
They found:
1.Using an intention-to-treat analysis, supplementation did not significantly reduce fracture rate.
2.But, of the 56.8% of the study participants who actually took the calcium, there was a reduced fracture rate ( hazard ratio 0.66) and improved bone density measurements.
So when viewed from a "public health perspective" it was not effective. However, calcium seems to work if you take the pills.
These results are similar to those of the recently published Woman's Health Study which also demonstrated that pills only work when you take them. Unlike the U.S. study this one did not find an increase in kidney stones. The misread and sometimes mis-reported results of the WHS may have lead some to stop their calcium in the belief that calcium supplemention does not help.
It does seem to decrease risk of fracture and it may even reduce the risk of colon polyps.
This was a 5 year, double blind, placebo-controlled trial of 1660 women older than 70 years of age.
They found:
1.Using an intention-to-treat analysis, supplementation did not significantly reduce fracture rate.
2.But, of the 56.8% of the study participants who actually took the calcium, there was a reduced fracture rate ( hazard ratio 0.66) and improved bone density measurements.
So when viewed from a "public health perspective" it was not effective. However, calcium seems to work if you take the pills.
These results are similar to those of the recently published Woman's Health Study which also demonstrated that pills only work when you take them. Unlike the U.S. study this one did not find an increase in kidney stones. The misread and sometimes mis-reported results of the WHS may have lead some to stop their calcium in the belief that calcium supplemention does not help.
It does seem to decrease risk of fracture and it may even reduce the risk of colon polyps.
More on bribing doctors to do their job
I recently posted on Dr. Faith Fitzgerald's principaled stand against pay for performance(P4P).
Ironically in the same issue of Internalmedicinenew.com, as Dr. Fitzgerald's article Dr. Christine K Cassel is featured promoting the ABIM scheme to tie "voluntary" reporting of quality data to obtain points to be used to obtain internist recertification and alleged future remuneration from Medicare.
The measurement of quality indicators is part of the ABIM's Practice Improvement Models (PIMs).
Dr. Cassel is trying to sell all of this because the collected quality data can be used"for multiple purposes."
Dr. Fitzgerald talked about "tipping doctors"for doing their duty.So far as regards CMS,there is just a promise of possible tipping in the future. ABIM seems to be making "an offer you can't refuse" by the threat of non-re certification for docs who don't play their quality game.
Some of us remember Dr. Cassel's commentary in the Annals of Internal Medicine in which she supported a flawed Annals article which bashed older docs in which she took the opportunity to promote the ABIM recertification dicta. See here for Dr. Roy Poses's comments regarding that issue. Promoting physician autonomy and the individual doctor patient relationship clearly is not part of the ABIM mission.
Ironically in the same issue of Internalmedicinenew.com, as Dr. Fitzgerald's article Dr. Christine K Cassel is featured promoting the ABIM scheme to tie "voluntary" reporting of quality data to obtain points to be used to obtain internist recertification and alleged future remuneration from Medicare.
The measurement of quality indicators is part of the ABIM's Practice Improvement Models (PIMs).
Dr. Cassel is trying to sell all of this because the collected quality data can be used"for multiple purposes."
Dr. Fitzgerald talked about "tipping doctors"for doing their duty.So far as regards CMS,there is just a promise of possible tipping in the future. ABIM seems to be making "an offer you can't refuse" by the threat of non-re certification for docs who don't play their quality game.
Some of us remember Dr. Cassel's commentary in the Annals of Internal Medicine in which she supported a flawed Annals article which bashed older docs in which she took the opportunity to promote the ABIM recertification dicta. See here for Dr. Roy Poses's comments regarding that issue. Promoting physician autonomy and the individual doctor patient relationship clearly is not part of the ABIM mission.
Thursday, April 27, 2006
Another argument against pay for performance (P4P) Should doctors be tipped?
Dr. Faith Fitzgerald,professor of Medicine at UC Davis,speaks out against P4P in the April 13,2006 issue of Internal Medicine News.(www.internalmedicinenews.com)
She makes two major points.
1)recommendations by "expert"panels are subject to reversal due to the fragile and provisional nature of medical conventional wisdom. Physicians feel bad when they make certain recommendations ( e.g. HRT for postmenopausal women) and later learn they may have harmed their patients, but at least they thought they were doing the right thing based on the information available at the time. However, with P4P, " Shall we have the same solace if we make these decisions,not because we think they are right but for money?
2"...the very concept of pay for performance for doctors,especially we when collaborate in the creating of the concept:Pay for performance embodies the tacit assumption that if we are not delivering it, it is because we are not being paid enough."...it[P4P] corrodes the conception of self-governance and correction that is part of the definition of professional. ...We must not servilely accept gratuities for doing our duty."
I believe P4P is wrong on so many levels. Thanks to Dr. Fitzgerald for emphasizing the aspect of how P4P is antithetical to physicians' professional identity.
She makes two major points.
1)recommendations by "expert"panels are subject to reversal due to the fragile and provisional nature of medical conventional wisdom. Physicians feel bad when they make certain recommendations ( e.g. HRT for postmenopausal women) and later learn they may have harmed their patients, but at least they thought they were doing the right thing based on the information available at the time. However, with P4P, " Shall we have the same solace if we make these decisions,not because we think they are right but for money?
2"...the very concept of pay for performance for doctors,especially we when collaborate in the creating of the concept:Pay for performance embodies the tacit assumption that if we are not delivering it, it is because we are not being paid enough."...it[P4P] corrodes the conception of self-governance and correction that is part of the definition of professional. ...We must not servilely accept gratuities for doing our duty."
I believe P4P is wrong on so many levels. Thanks to Dr. Fitzgerald for emphasizing the aspect of how P4P is antithetical to physicians' professional identity.
Subscribe to:
Posts (Atom)